SG11201804050QA - A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic - Google Patents
A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergicInfo
- Publication number
- SG11201804050QA SG11201804050QA SG11201804050QA SG11201804050QA SG11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA SG 11201804050Q A SG11201804050Q A SG 11201804050QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- parma
- corticosteroid
- dry powder
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau 1111111111111101110111111111110101111100111111H1111111111111111111111111111110111111 (43) International Publication Date 26 May 2017 (26.05.2017) (10) International Publication Number WO 2017/085004 Al WIPO I PCT (51) International Patent Classification: A61K 9/14 (2006.01) A61K 31/00 (2006.01) A61K 47/12 (2006.01) A61K 9/00 (2006.01) A61K 47/26 (2006.01) (21) International Application Number: PCT/EP2016/077558 (22) International Filing Date: 14 November 2016 (14.11.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15194660.5 16 November 2015 (16.11.2015) EP (71) Applicant: CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, 43122 Parma (IT). (72) Inventors: CAFIERO, Claudio; c/o CHIESI FARMA- CEUTICI S.p.A., Via Palermo, 26/A, 43122 Parma (IT). ORTENZI, Leonardo; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 Parma (IT). SCHIAR- ETTI, Francesca; c/o CHIESI FARMACEUTICI S.p.A., Via Palermo, 26/A, 43122 Parma (IT). (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.1., Via Plinio, 63, 20129 Milano (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) W O 20 17 /085 00 4 Al (54) Title: A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC (57) : The invention relates to a dry powder formulation for inhalation comprising a combination of an anti-cholinergic, a long-acting beta 2 -adrenoceptor agonist, and a corticosteroid, and to a process for preparation thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194660 | 2015-11-16 | ||
PCT/EP2016/077558 WO2017085004A1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804050QA true SG11201804050QA (en) | 2018-06-28 |
Family
ID=54548062
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804050QA SG11201804050QA (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
SG10201912093YA SG10201912093YA (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912093YA SG10201912093YA (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Country Status (36)
Country | Link |
---|---|
US (4) | US10086004B2 (en) |
EP (3) | EP3628331B1 (en) |
JP (1) | JP6963548B2 (en) |
KR (1) | KR20180082443A (en) |
CN (1) | CN108289962B (en) |
AR (1) | AR106688A1 (en) |
AU (1) | AU2016356858B2 (en) |
CA (1) | CA3005290A1 (en) |
CL (1) | CL2018001298A1 (en) |
CO (1) | CO2018005141A2 (en) |
CY (3) | CY1123042T1 (en) |
DK (3) | DK3620176T3 (en) |
EA (1) | EA037716B1 (en) |
ES (3) | ES2895687T3 (en) |
GE (1) | GEP20207157B (en) |
HR (3) | HRP20211598T1 (en) |
HU (3) | HUE056441T2 (en) |
IL (1) | IL259329B (en) |
LT (3) | LT3620176T (en) |
MA (3) | MA50487B1 (en) |
MD (3) | MD3377108T2 (en) |
ME (1) | ME03778B (en) |
MX (1) | MX2018005977A (en) |
MY (1) | MY186229A (en) |
PE (1) | PE20181488A1 (en) |
PH (1) | PH12018501022A1 (en) |
PL (3) | PL3628331T3 (en) |
PT (3) | PT3620176T (en) |
RS (3) | RS62404B1 (en) |
SA (1) | SA518391570B1 (en) |
SG (2) | SG11201804050QA (en) |
SI (3) | SI3377108T1 (en) |
TW (1) | TWI731891B (en) |
UA (1) | UA125019C2 (en) |
WO (1) | WO2017085004A1 (en) |
ZA (1) | ZA201803168B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3060020A1 (en) * | 2017-05-11 | 2018-11-15 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
CN110612095A (en) * | 2017-05-11 | 2019-12-24 | 奇斯药制品公司 | Method for preparing dry powder formulations comprising anticholinergics, corticosteroids and beta-adrenergic agents |
US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
WO2020198716A1 (en) * | 2019-03-27 | 2020-10-01 | Kemin Industries, Inc. | Methods for preparing metal carboxylates in one-pot reaction |
CN112137957B (en) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | Medicinal inhalation aerosol and preparation method thereof |
WO2021143785A1 (en) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | Pharmaceutical composition of aerosol inhalant containing indacaterol and preparation method thereof |
WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
US20220304894A1 (en) * | 2021-03-24 | 2022-09-29 | Cmpd Licensing, Llc | Drug powderization within vials |
WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20011227A1 (en) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES |
GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
DE60239639D1 (en) | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | powder inhaler |
EA021917B1 (en) * | 2009-12-23 | 2015-09-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Combination therapy for asthma and copd |
PL2928889T3 (en) * | 2012-12-06 | 2018-09-28 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
RU2661877C2 (en) * | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Compounds having muscarinic receptor antagonist and beta-2-adrenergic receptor agonist activity |
US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
HUE053957T2 (en) * | 2013-07-11 | 2021-08-30 | Chiesi Farm Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
-
2016
- 2016-11-14 HR HRP20211598TT patent/HRP20211598T1/en unknown
- 2016-11-14 MD MDE20180917T patent/MD3377108T2/en unknown
- 2016-11-14 AR ARP160103473A patent/AR106688A1/en unknown
- 2016-11-14 MD MDE20200898T patent/MD3628331T2/en unknown
- 2016-11-14 SI SI201630682T patent/SI3377108T1/en unknown
- 2016-11-14 MX MX2018005977A patent/MX2018005977A/en unknown
- 2016-11-14 RS RS20211196A patent/RS62404B1/en unknown
- 2016-11-14 MA MA50487A patent/MA50487B1/en unknown
- 2016-11-14 PT PT192059806T patent/PT3620176T/en unknown
- 2016-11-14 SI SI201631349T patent/SI3628331T1/en unknown
- 2016-11-14 PL PL19205936T patent/PL3628331T3/en unknown
- 2016-11-14 WO PCT/EP2016/077558 patent/WO2017085004A1/en active Application Filing
- 2016-11-14 JP JP2018524832A patent/JP6963548B2/en active Active
- 2016-11-14 MD MDE20200899T patent/MD3620176T2/en unknown
- 2016-11-14 EA EA201890966A patent/EA037716B1/en unknown
- 2016-11-14 RS RS20200440A patent/RS60171B1/en unknown
- 2016-11-14 PE PE2018000973A patent/PE20181488A1/en unknown
- 2016-11-14 ME MEP-2020-80A patent/ME03778B/en unknown
- 2016-11-14 CA CA3005290A patent/CA3005290A1/en active Pending
- 2016-11-14 SG SG11201804050QA patent/SG11201804050QA/en unknown
- 2016-11-14 RS RS20211283A patent/RS62506B1/en unknown
- 2016-11-14 AU AU2016356858A patent/AU2016356858B2/en active Active
- 2016-11-14 UA UAA201805271A patent/UA125019C2/en unknown
- 2016-11-14 HU HUE19205980A patent/HUE056441T2/en unknown
- 2016-11-14 SG SG10201912093YA patent/SG10201912093YA/en unknown
- 2016-11-14 LT LTEP19205980.6T patent/LT3620176T/en unknown
- 2016-11-14 ES ES19205936T patent/ES2895687T3/en active Active
- 2016-11-14 SI SI201631331T patent/SI3620176T1/en unknown
- 2016-11-14 CN CN201680066801.5A patent/CN108289962B/en active Active
- 2016-11-14 PT PT192059368T patent/PT3628331T/en unknown
- 2016-11-14 PL PL19205980T patent/PL3620176T3/en unknown
- 2016-11-14 MY MYPI2018000704A patent/MY186229A/en unknown
- 2016-11-14 LT LTEP16801982.6T patent/LT3377108T/en unknown
- 2016-11-14 GE GEAP201614783A patent/GEP20207157B/en unknown
- 2016-11-14 EP EP19205936.8A patent/EP3628331B1/en active Active
- 2016-11-14 HU HUE19205936A patent/HUE056260T2/en unknown
- 2016-11-14 ES ES19205980T patent/ES2891073T3/en active Active
- 2016-11-14 DK DK19205980.6T patent/DK3620176T3/en active
- 2016-11-14 EP EP16801982.6A patent/EP3377108B1/en active Active
- 2016-11-14 EP EP19205980.6A patent/EP3620176B1/en active Active
- 2016-11-14 PT PT168019826T patent/PT3377108T/en unknown
- 2016-11-14 TW TW105137048A patent/TWI731891B/en active
- 2016-11-14 PL PL16801982T patent/PL3377108T3/en unknown
- 2016-11-14 HR HRP20211600TT patent/HRP20211600T1/en unknown
- 2016-11-14 DK DK16801982.6T patent/DK3377108T3/en active
- 2016-11-14 ES ES16801982T patent/ES2783855T3/en active Active
- 2016-11-14 MA MA43256A patent/MA43256B1/en unknown
- 2016-11-14 HU HUE16801982A patent/HUE049751T2/en unknown
- 2016-11-14 LT LTEP19205936.8T patent/LT3628331T/en unknown
- 2016-11-14 DK DK19205936.8T patent/DK3628331T3/en active
- 2016-11-14 KR KR1020187013286A patent/KR20180082443A/en unknown
- 2016-11-14 MA MA50488A patent/MA50488B1/en unknown
- 2016-11-15 US US15/351,562 patent/US10086004B2/en active Active
-
2018
- 2018-05-14 SA SA518391570A patent/SA518391570B1/en unknown
- 2018-05-14 ZA ZA2018/03168A patent/ZA201803168B/en unknown
- 2018-05-14 CL CL2018001298A patent/CL2018001298A1/en unknown
- 2018-05-14 IL IL259329A patent/IL259329B/en active IP Right Grant
- 2018-05-15 PH PH12018501022A patent/PH12018501022A1/en unknown
- 2018-05-16 CO CONC2018/0005141A patent/CO2018005141A2/en unknown
- 2018-08-27 US US16/113,026 patent/US10772896B2/en active Active
-
2020
- 2020-04-01 HR HRP20200537TT patent/HRP20200537T1/en unknown
- 2020-04-06 CY CY20201100319T patent/CY1123042T1/en unknown
- 2020-08-07 US US16/987,695 patent/US10966991B2/en active Active
-
2021
- 2021-02-24 US US17/184,181 patent/US11628175B2/en active Active
- 2021-09-07 CY CY20211100793T patent/CY1124475T1/en unknown
- 2021-09-09 CY CY20211100797T patent/CY1124490T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804050QA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
SG11201804048WA (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
SG11201901141WA (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
SG11201903331QA (en) | Restimulation of cryopreserved tumor infiltrating lymphocytes | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201808108XA (en) | Synthesis of indazoles | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201402986RA (en) | Kinase inhibitors | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201900618WA (en) | Permanently polarized hydroxyapatite, a process for its manufacture and uses thereof | |
SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
SG11201809356YA (en) | Multilayer coating and process of preparing the multilayer coating | |
SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
SG11202000141WA (en) | Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof | |
SG11201909366XA (en) | Method for preparing and analyzing fluorescent compounds in plasma | |
SG11201407114YA (en) | Novel dosage and formulation | |
SG11201809671PA (en) | Imidazolone compounds as human neutrophil elastase inhibitors |